BofA raised the firm’s price target on Argenx (ARGX) to $761 from $717 and keeps a Buy rating on the shares. The firm remains “bullish” on the commercial opportunity for Vyvgart and Vyvgart Hytrulo with potential upside from the potential approval of the PFS that has an April 10 PDUFA action date and several long-term value drivers in the pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
- Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment
- Argenx announces Japan MHLW approval for Vyvdura for CIDP
- Argenx price target raised to $723 from $639 at Wells Fargo
- Argenx price target raised to EUR 740 from EUR 620 at JPMorgan